CTRI/2021/12/038868
Not yet recruiting
未知
Evaluation of efficacy and safety of daily versus alternate day dapagliflozin therapy among patients with type 2 diabetes mellitus: An open label randomized controlled study - DAPA-ADT
Department of Science Technology Renewable Energy Chandigarh Administration Chandigarh0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complicationsHealth Condition 2: E119- Type 2 diabetes mellitus without complications
- Sponsor
- Department of Science Technology Renewable Energy Chandigarh Administration Chandigarh
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male and female patients with T2DM visiting the General Medicine/Endocrinology OPD/Ward who are taking stable dose of metformin more than or equal to 1500 mg per day therapy for a duration 3 months or more.
- •2\.Age 18\-59 years
- •3\.Glycosylated hemoglobin (HbA1c) values between 7\-9%
Exclusion Criteria
- •\- Subjects with type 1 DM
- •\-Patients who have taken metformin treatment for a duration of less than 3 months
- •\-Patients taking add on anti\-diabetic drugs over and above metformin
- •\-Patients having allergy to any of the study drugs
- •\-Pregnant and lactating women
- •\-Patients with kidney dysfunction (serum
- •creatinine level more than 1\.5 times more than the upper limit of normal range)
- •\- Patients with hepatic dysfunction (alanine aminotransferase and/or aspartate aminotransferase levels 3\-fold more than the upper limit of normal range)
- •\-Patients having acute infections, recent trauma or surgery for which the treatment is ongoing and patients have not yet recovered
- •\-Patients with history of recent diabetic ketoacidosis
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Comparable efficacy and safety profiles of daily injection of BK0023 and filgrastim (Neupogen®) in chemotherapy-induced neutropenia: a multinational, multicenter, investigator blind, randomised, parallel group study in women with breast cancerEUCTR2007-007161-20-BGBIO-KER S.R.288
Not yet recruiting
Phase 1
Comparing the Effectiveness of Daily VS Every other day of Oral Astaxanthin on Improvement Skin Elasticity, A Randomized, Double-blind Clinical TrialHealthy women and elasticityTCTR20210321001one40
Active, not recruiting
Phase 1
Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitusEUCTR2014-001540-38-GBovo Nordisk A/S957
Active, not recruiting
Phase 1
Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitusObesityMedDRA version: 18.1Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2014-001540-38-BEovo Nordisk A/S935
Active, not recruiting
Phase 1
Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitusEUCTR2014-001540-38-DEovo Nordisk A/S935